Professor Angus Dalgliesh graduated from University College Hospital, London and obtained an MBBS with an intercalated BSc Hons in Anatomy under Professor J. J. Young, FRS.
He specialised in Oncology at the Royal Brisbane Hospital, Mater and Chermside Hospitals in Brisbane before moving to the Ludwig Institute in Sydney at the Royal Prince Alfred Hospital.
After completing his training, he returned to the UK in 1984 to work as a Clinical Research Fellow with Professor Robin Weiss FRS, who was then the Director of the Institute of Cancer Research, and later worked in an honorary clinical position at the Royal Marsden Hospital with Dr Wiltshore. In 1986, Professor Dalgliesh was appointed MRC Clinical Scientist and honorary Consultant in General Medicine, Immunology and Oncology at the Clinical Research Centre at Northwick Park Hospital.
In 1991, Professor Dalgliesh was made Foundation Chair of Oncology at St. George's University of London and NHS Hospital and developed an interest in the immune system to treat cancer. He had already gained previous experience in studies using high dose IL-2 and Interferon and subsequently developed an interest in the potential of vaccines to treat cancer. Positive phase II studies have led to the largest double blind phase III study in the world, of which Professor Dalgliesh is the only Principal Investigator in the UK. In 1997 he founded Onyvax Ltd, a privately funded company dedicated to the development of cancer vaccines.
Professor Dalgliesh has held grants from all the major funding agencies and is on the Grant Committee for Cancer Projects at the European Commission. He has published over 260 peer reviewed publications and has co-edited 4 text books, contributing towards over 40 chapters.
Some of Professor Dalgleish's key papers are as follows:
Dalgleish AG. Cancer and Inflammation. Br. J. Cancer. 2005 Feb28;92(4):792-3.
Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit, H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG. Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. British Journal of Cancer 2004(90);955-961.
Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysat-pulsed cells: a phase I/II study. BJU Int. 2004 Aug:94(3):412-8.
Schey, SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004 Aug 15,22(16):3269-76.
Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its ImiD derivatives as anticancer agents. Nat Rev Cancer. 2004 Apr:4(4):314-22.
Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man HW, Schafer P, Grovinda S, Muller GW, Stirling DI, Dalgleish AG. A novel subclass of thalidomide analogue with anti-solid tumor activity which caspase-dependent apoptosis is associated with altered expression Bcl-2 family proteins. Cancer Res. 2003:1:63(3):593-9.
Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG. A randomized phase II trial of SRL172 (Mycobacterium vaccae)+/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res. 2003 Aug:13(14);389-93.
John J, Hutchinson J, Dalgleish AG& Pandha H. Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction. J Immunol Methods. (2003) 272, 35-48.
Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI &Dalgleish AG Protective antitumour immunity induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumour Cell Vaccination is Mediated by Increased Th1-type Immunity. J Immunol. (2002) 16, 4914-9.
O'Byrne KJ &Dalgleish AG Chronic Immune Activation and Inflammation as the Cause of Malignancy Br J Cancer (2001). 85, 473-83.
Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.
We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.